Evidence map›Paper›PMID 24508806›Full record

ArticleInternational journal of pharmaceutics2014

Layer-by-layer nanoencapsulation of camptothecin with improved activity.

Gaurav Parekh, Pravin Pattekari, Chaitanya Joshi, Tatsiana Shutava, Mark DeCoster, Tatyana Levchenko, Vladimir Torchilin, Yuri Lvov

Abstract read
In one paragraph

Article in International journal of pharmaceutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. The Use of Poly(Polymers · 2020
    Review
  4. Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2019
    Article
  5. Article
  6. Engineering nanolayered particles for modular drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2016
    Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Gaurav ParekhInstitute for Micromanufacturing and Biomedical Engineering Program, Louisiana Tech University, USA.
Pravin PattekariInstitute for Micromanufacturing and Biomedical Engineering Program, Louisiana Tech University, USA.
Chaitanya JoshiInstitute for Micromanufacturing and Biomedical Engineering Program, Louisiana Tech University, USA.
Tatsiana ShutavaInstitute for Micromanufacturing and Biomedical Engineering Program, Louisiana Tech University, USA.
Mark DeCosterInstitute for Micromanufacturing and Biomedical Engineering Program, Louisiana Tech University, USA.
Tatyana LevchenkoDepartment of Pharmaceutical Sciences, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA.
Vladimir TorchilinDepartment of Pharmaceutical Sciences, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA.
Yuri LvovInstitute for Micromanufacturing and Biomedical Engineering Program, Louisiana Tech University, USA. Electronic address: ylvov@latech.edu.
Louisiana Tech University · USNortheastern University · US

Funding

Layer-by-layer nanocarriers for highly efficient solubilization of insoluble drugR01CA134951 · NCI · NORTHEASTERN UNIVERSITY · PI TORCHILIN, VLADIMIR P · 2010 to 2013
$1.3M
NCI NIH HHS 1R01CA134951NCI NIH HHS R01 CA134951
6 · The paper itself

Abstract

160 nm nanocapsules containing up to 60% of camptothecin in the core and 7-8 polyelectrolyte bilayers in the shell were produced by washless layer-by-layer assembly of heparin and block-copolymer of poly-l-lysine and polyethylene glycol. The outer surface of the nanocapsules was additionally modified with polyethylene glycol of 5 kDa or 20 kDa molecular weight to attain protein resistant properties, colloidal stability in serum and prolonged release of the drug from the capsules. An advantage of the LbL coated capsules is the preservation of camptothecin lactone form with the shell assembly starting at acidic pH and improved chemical stability of encapsulated drug at neutral and basic pH, especially in the presence of albumin that makes such formulation more active than free camptothecin. LbL nanocapsules preserve the camptothecin lactone form at pH 7.4 resulting in triple activity of the drug toward CRL2303 glioblastoma cell.

Indexed as

NanocapsulesAnimalsAntineoplastic Agents, PhytogenicBrain NeoplasmsCamptothecinCell Line, TumorCell SurvivalChemistry, PharmaceuticalDrug CompoundingDrug StabilityGlioblastomaHeparinHydrogen-Ion ConcentrationHydrolysisKineticsMolecular WeightAntineoplastic Agents, PhytogenicCamptothecinHeparinNanocapsulesPolyethylene GlycolsPolylysinePolymersCamptothecinCytotoxicGlioblastomaLactoneLayer-by-layerNanocapsules

Identifiers

PMID24508806
PMCPMC4015802
OpenAlexW1974241574

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.